Research Claim Grammar Predicts Commercial Readiness as 23.0% of Assertive Records Rate High Against 5.1% of Conditional Records Across 3,581 Research Records

InnoDexis has published its latest Innovation Intelligence Report covering the research innovation landscape, analyzing 3,581 research records from 1,022 institutions in 38 countries, naming 12,797 distinct lead scientists, during the 1–29 September 2026 observation window across 14 technology families. The report reveals that readiness is written in the grammar: 70.7 percent of records carry a Low commercial-readiness rating, only 1.0 percent describe something launched, and assertive disruption claims are rated High for readiness 23.0 percent of the time against 5.1 percent for conditional ones.

Key Findings

The stream is early-stage. Half the stream, 1,792 records or 50.0 percent, is concepts and evidence studies, 937 are prototypes, 684 are clinical, pilot or field-stage, 131 carry a named company formation and only 37, 1.0 percent, describe something launched, while medtech is the most applied large family at 23.9 percent High readiness.

Claim grammar predicts readiness. Where the disruption claim is assertive, 23.0 percent of records are rated High readiness, against 5.1 percent where it is conditional, a ratio of 4.5 to 1 across 3,261 records, with hedged claims at 9.4 percent.

Depth and readiness are inverse. Records rated High for scientific deep-dive potential are rated High for commercial readiness 6.0 percent of the time, against 28.4 percent for records rated Low for depth, and fundamental science carries only 2.6 percent High readiness.

Evidence, not cost, constrains research. Of 3,447 populated research-gap entries, 814 cite long-term follow-up or durability, 737 human or clinical validation, 545 mechanism, 414 larger or more diverse samples and 218 field validation, against 258 for scale-up and only 53 for cost.

Research is publicly funded at announcement. Government grants are named in 41.9 percent of records and R&D collaborations in 40.8 percent, while corporations are named in only 15.4 percent and venture investment is essentially absent. Lead scientists are named on 95.7 percent of records.

Strategic Insight and Trend Analysis

The defining structural finding is that research readiness is legible in text. The mood of the disruption claim and the scientific deep-dive rating together let a scout reduce 3,581 records to roughly 1,175 assertive records, or to the 407 rated High, and the 1,175 assertive records hold most of the stream’s near-use work while the 2,086 conditional records are mostly discovery science. Grammar reflects how confident the source is as well as how ready the work is, so it prioritises reading and does not replace it.

The stream is weighted to health and fundamental science, with a thin applied edge. Health, behaviour and social science at 709 records, therapeutics and biotech at 416 and earth, life and fundamental science at 392 account for 42.4 percent of records, and research outnumbers corporate records ten to one in fundamental science, while fintech, cybersecurity and consumer technology barely appear. Germany is the most distributed system, with 763 records across 305 institutions, while China is concentrated, with 130 records across 18.

Corporations sit inside research before they announce. Eli Lilly is named in 10 records, Google, AstraZeneca, Sanofi and Pfizer in 9 each, and Novo Nordisk and Takeda in 8, and cross-stream verification confirms 231 organisations as parties to corporate records, from 808 raw matches, a correction factor of 3.5. The bridges are platforms and pharmaceutical companies, not universities, which makes the research stream a competitive-intelligence source on who is working with whom.

Global and Industry Implications

For corporates and R&D teams, the corporations field is a competitive-intelligence source on who is working with whom, and a sourcing map by country: German energy, process and photonics research, US therapeutics and AI, and Korean materials. Sponsoring device research at research-agreement cost is open in novel electronic materials, 32 records, quantum, 16, and photonics, 59.

For investors and capital allocators, the 131 formation records and 407 High-readiness records are the investable surface, since venture investment is essentially absent at announcement. Formations resting on a measured comparator and a named regulatory or manufacturing route, such as ART-EMIS Hamburg with a CE Class IIb tool that rules out heart attack safely in 36 percent of patients against 14 percent, fit best.

For policymakers and national innovation bodies, the binding gaps are evidence gaps, long-term follow-up at 814 entries, human validation at 737 and diverse samples at 414, which public registries and cohort infrastructure can supply more cheaply than individual grants. Regulatory pathways are explicit in the stream: 660 records name a marketing approval, 242 an IND and 212 a device pathway.

InnoDexis Statement

“Readiness is written in the grammar — assertive claims are rated High for commercial readiness 4.5 times as often as conditional ones, while in this stream the deepest science sits furthest from use,” noted InnoDexis in its latest intelligence report.

Conclusion

As a baseline edition drawn from one month, with English-language orientation shaping country counts and 78 German–English duplicates collapsed, the report states cross-sectional findings rather than trends. The signals to watch are whether formations rise above 5 percent of records, whether pilot and field-stage shares rise in materials, semiconductors, energy and robotics, whether named spin-outs raise rounds, and whether long-term follow-up and human-validation gaps begin to close. Each is a specific, observable test. The complete Research Innovation Landscape Report September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.